Pfiz­er nabs dis­count­ed stake in Zen­tal­is af­ter AACR22 da­ta left the biotech bruised

Af­ter a dis­ap­point­ing da­ta re­lease at AACR bat­tered its stock, Zen­tal­is Phar­ma­ceu­ti­cals is look­ing to re­bound with a sev­en-fig­ure eq­ui­ty in­vest­ment from a phar­ma­ceu­ti­cal com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER